Lilly charts strong growth in animal health; Phibro teams up with Merial on vaccine technology;

> Eli Lilly ($LLY) announced that sales in its animal health division rose 9% year over year in the fourth quarter of 2014, to $633.3 million, while full-year sales were also up 9% to $2.3 billion. Release

> Phibro Animal Health ($PAHC) struck a licensing deal with Sanofi's ($SNY) Merial, which plans to use Phibro's delivery technology in animal vaccines. Release

> In his 2016 budget proposal, President Obama plans to nearly double federal funding for combating antibiotic resistance, to $1.2 billion, which will greatly increase R&D funds available for improving animal-care practices. Article

> Heska ($HSKA) has formed a distribution agreement with the Canadian division of scil, which will market Heska's hematology and chemistry instruments. Release

> An international team of scientists has discovered that canine distemper virus, which has been infecting lions in Tanzania's Serengeti National Park, can be spread by a variety of wild animals, not just by domestic dogs and coyotes. Release

Suggested Articles

Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…